160 related articles for article (PubMed ID: 38763916)
1. Role of ammonia and glutamine in the pathogenesis and progression of metabolic dysfunction-associated steatotic liver disease: A systematic review.
Njei B; Al-Ajlouni YA; Ameyaw P; Njei LP; Boateng S
J Gastroenterol Hepatol; 2024 May; ():. PubMed ID: 38763916
[TBL] [Abstract][Full Text] [Related]
2. Pathology and Pathogenesis of Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatic Tumors.
Takahashi Y; Dungubat E; Kusano H; Fukusato T
Biomedicines; 2023 Oct; 11(10):. PubMed ID: 37893134
[TBL] [Abstract][Full Text] [Related]
3. The lipopolysaccharide-TLR4 axis regulates hepatic glutaminase 1 expression promoting liver ammonia build-up as steatotic liver disease progresses to steatohepatitis.
Mercado-Gómez M; Goikoetxea-Usandizaga N; Kerbert AJC; Gracianteparaluceta LU; Serrano-Maciá M; Lachiondo-Ortega S; Rodriguez-Agudo R; Gil-Pitarch C; Simón J; González-Recio I; Fondevila MF; Santamarina-Ojeda P; Fraga MF; Nogueiras R; Heras JL; Jalan R; Martínez-Chantar ML; Delgado TC
Metabolism; 2024 Jun; 158():155952. PubMed ID: 38906371
[TBL] [Abstract][Full Text] [Related]
4. Phenotypes of Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatocellular Carcinoma.
Rivera-Esteban J; Muñoz-Martínez S; Higuera M; Sena E; Bermúdez-Ramos M; Bañares J; Martínez-Gomez M; Cusidó MS; Jiménez-Masip A; Francque SM; Tacke F; Minguez B; Pericàs JM
Clin Gastroenterol Hepatol; 2024 Apr; ():. PubMed ID: 38604295
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological therapy of metabolic dysfunction-associated steatotic liver disease-driven hepatocellular carcinoma.
Wang Y; Fleishman JS; Li T; Li Y; Ren Z; Chen J; Ding M
Front Pharmacol; 2023; 14():1336216. PubMed ID: 38313077
[TBL] [Abstract][Full Text] [Related]
6. Myosteatosis: Diagnosis, pathophysiology and consequences in metabolic dysfunction-associated steatotic liver disease.
Henin G; Loumaye A; Leclercq IA; Lanthier N
JHEP Rep; 2024 Feb; 6(2):100963. PubMed ID: 38322420
[TBL] [Abstract][Full Text] [Related]
7. Elucidating cuproptosis in metabolic dysfunction-associated steatotic liver disease.
Li Y; Qi P; Song SY; Wang Y; Wang H; Cao P; Liu Y; Wang Y
Biomed Pharmacother; 2024 May; 174():116585. PubMed ID: 38615611
[TBL] [Abstract][Full Text] [Related]
8. The Lasting Effects of COVID-19 on the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
Backer S; Khanna D
Cureus; 2023 Sep; 15(9):e45231. PubMed ID: 37842470
[TBL] [Abstract][Full Text] [Related]
9. Vitamin D and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Novel Mechanistic Insights.
Aggeletopoulou I; Tsounis EP; Triantos C
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732118
[TBL] [Abstract][Full Text] [Related]
10. The pathophysiology of MASLD: an immunometabolic perspective.
Schwärzler J; Grabherr F; Grander C; Adolph TE; Tilg H
Expert Rev Clin Immunol; 2024 Apr; 20(4):375-386. PubMed ID: 38149354
[TBL] [Abstract][Full Text] [Related]
11. Familial coaggregation of MASLD with hepatocellular carcinoma and adverse liver outcomes: Nationwide multigenerational cohort study.
Ebrahimi F; Hagström H; Sun J; Bergman D; Shang Y; Yang W; Roelstraete B; Ludvigsson JF
J Hepatol; 2023 Dec; 79(6):1374-1384. PubMed ID: 37647992
[TBL] [Abstract][Full Text] [Related]
12. Nuclear miR-204-3p mitigates metabolic dysfunction-associated steatotic liver disease in mice.
Zou Z; Liu X; Yu J; Ban T; Zhang Z; Wang P; Huang R; Zheng F; Chang Y; Peng W; Tang Y; Feng X; Zhao Z; Lv X; Huang S; Guo J; Tuo Y; Zhou Z; Liang S
J Hepatol; 2024 Jun; 80(6):834-845. PubMed ID: 38331323
[TBL] [Abstract][Full Text] [Related]
13. Update in lean metabolic dysfunction-associated steatotic liver disease.
Sato-Espinoza K; Chotiprasidhi P; Huaman MR; Díaz-Ferrer J
World J Hepatol; 2024 Mar; 16(3):452-464. PubMed ID: 38577539
[TBL] [Abstract][Full Text] [Related]
14. Roles of immune dysregulation in MASLD.
Dong T; Li J; Liu Y; Zhou S; Wei X; Hua H; Tang K; Zhang X; Wang Y; Wu Z; Gao C; Zhang H
Biomed Pharmacother; 2024 Jan; 170():116069. PubMed ID: 38147736
[TBL] [Abstract][Full Text] [Related]
15. Cognitive dysfunction in early experimental metabolic dysfunction-associated steatotic liver disease is associated with systemic inflammation and neuroinflammation.
Kjærgaard K; Daugaard Mikkelsen AC; Landau AM; Eriksen PL; Hamilton-Dutoit S; Magnusson NE; Thomsen MB; Chen F; Vilstrup H; Mookerjee RP; Bay-Richter C; Thomsen KL
JHEP Rep; 2024 Mar; 6(3):100992. PubMed ID: 38415019
[TBL] [Abstract][Full Text] [Related]
16. Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis: The Patient and Physician Perspective.
Eskridge W; Cryer DR; Schattenberg JM; Gastaldelli A; Malhi H; Allen AM; Noureddin M; Sanyal AJ
J Clin Med; 2023 Sep; 12(19):. PubMed ID: 37834859
[TBL] [Abstract][Full Text] [Related]
17. Mitochondrial Quality Control: Its Role in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
Shin S; Kim J; Lee JY; Kim J; Oh CM
J Obes Metab Syndr; 2023 Dec; 32(4):289-302. PubMed ID: 38049180
[TBL] [Abstract][Full Text] [Related]
18. Adipocytokines as Predictors of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Development in Type 2 Diabetes Mellitus Patients.
Fajkić A; Jahić R; Hadžović-Džuvo A; Lepara O
Cureus; 2024 Mar; 16(3):e55673. PubMed ID: 38455340
[TBL] [Abstract][Full Text] [Related]
19. Glutamine synthetase and hepatocellular carcinoma.
Jiang J; Hu Y; Fang D; Luo J
Clin Res Hepatol Gastroenterol; 2023 Dec; 47(10):102248. PubMed ID: 37979911
[TBL] [Abstract][Full Text] [Related]
20. Autophagy, Ferroptosis, Apoptosis and Pyroptosis in Metabolic Dysfunction-Associated Steatotic Liver Disease.
Zhao S; Guo Y; Yin X
Front Biosci (Landmark Ed); 2024 Jan; 29(1):30. PubMed ID: 38287834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]